Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF-κB Pathway
Hui Zhang,Jinyi Lin,Yihui Shen,Jianan Pan,ChunHui Wang,Leilei Cheng
DOI: https://doi.org/10.2147/JIR.S348464
IF: 4.5
2022-03-05
Journal of Inflammation Research
Abstract:Hui Zhang, 1, &ast Jinyi Lin, 2, &ast Yihui Shen, 1 Jianan Pan, 3 Chunhui Wang, 4 Leilei Cheng 1 1 Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Shanghai, People's Republic of China; 2 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, People's Republic of China; 3 Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, People's Republic of China; 4 Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Leilei Cheng, Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Shanghai, 200032, People's Republic of China, Fax +86-21-51217561, Email Purpose: Immune checkpoint inhibitors (ICIs)-related myocarditis is now one of the most critical immune-related adverse effects (irAEs) in tumor immunotherapy, which has raised great concern in cardio-oncology. The pathogenesis involved in cardiac injury remains elusive. Crocin, the main component of saffron, has shown distinct functions in cardioprotective and anti-inflammation properties. We therefore aimed to investigate the potential effect of crocin on the protection of ICIs-related myocarditis and its underlying molecular mechanism. Methods: We immunized the BALB/c mice with murine cardiac troponin I (cTnI) peptide and additionally gave anti-mouse programmed death 1 (PD-1) to induce the mouse model of ICIs-related myocarditis. Mice were treated with crocin at different dosages. In vitro, HL-1 cells were pre-incubated with crocin at different concentrations and then stimulated with lipopolysaccharide (LPS). Myocardial contractile functions, myocardial inflammation and fibrosis, and myocardial injury were assessed. The expressions of pyroptosis-related proteins and nuclear factor-κB (NF-κB) pathway were evaluated. Results: Crocin treatment could partially reverse the ICIs-related myocarditis in terms of improving heart function, ameliorating inflammation and fibrosis in the myocardium, and alleviating myocardial injury. Mechanistically, ICIs administration significantly activated pyrin domain-containing protein 3 (NLRP3) inflammasome in cardiomyocytes. Crocin treatments significantly downregulated the expression of NLRP3, cleaved gasdermin D (GSDMD), cleaved caspase1, interleukin-1β (IL-1β), and IL-18. Besides, crocin inhibited the activation of NF-κB pathway, which performed as reducing the phosphorylation of p-NF-kappa-B inhibitor-α (p-IκBα), degradation of IκBα, phosphorylation of p65 and p65 DNA binding activity both in vivo and in vitro. Conclusion: By reversing the pyroptosis in cardiomyocytes, crocin treatment in a mouse model exerted great potential to aid in the prevention of ICIs-related myocarditis from a novel target. Graphical Keywords: cardio-oncology, immune checkpoint inhibitors, autoimmune myocarditis, programmed death 1, immune-related adverse effects Graphical In the past decade, the rise and development of immune checkpoint inhibitors (ICIs) have brought great clinical advances in cancer immunotherapy. 1,2 ICIs target different immune checkpoints including the programmed death 1 (PD-1) such as Nivolumab and Pembrolizumab, programmed death ligand 1 (PD-L1) like Atezolizumab, Avelumab, and Durvalumab, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors like Tremelimumab and Ipilimumab. 3 Since immune checkpoints also play a critical role in autoimmune tolerance, the activation of the immune system by ICIs may cause a wide range of autoimmune responses, which is called immune-related adverse effects (irAEs), including colitis, hepatitis, pneumonitis, thyroiditis, myositis, hypophysitis, and dermatitis. 4–6 These irAEs are largely reversible and can typically be controlled with the administration of glucocorticoid therapy. 5–7 However, severe cardiovascular effects, especially myocarditis and fatal heart failure caused by ICIs, have largely been underestimated in the past few years, which has raised great concern in cardio-oncology. 8 In 2018, a multicenter clinical study showed that the incidence of ICIs-related myocarditis was 1.14%. 9 In addition, the onset of ICIs-related myocarditis could be as early as 2 weeks after ICIs initiated, 10 the median ti -Abstract Truncated-
immunology